Press Release
February 9, 2024

BridgeBio Pharma and QED Therapeutics License Skeletal Dysplasias Treatments to Kyowa Kirin for an Upfront Payment of $100 Million Plus Milestones

The Life Sciences team advised BridgeBio Pharma (Nasdaq: BBIO)  and QED Therapeutics (“QED”) in their executed exclusive license with Kyowa Kirin (“KKC”) to develop and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. In exchange, QED will receive an upfront payment of USD $100 million as well as royalties up to the high-twenties percent on sales of infigratinib in Japan, with the potential for additional milestone-based payments.

BBIO, headquartered in Palo Alto, CA, is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BBIO’s pipeline of development programs ranges from early science to advanced clinical trials. BBIO was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. 

QED, headquartered in San Francisco, CA and an affiliate of BBIO, is a biotechnology company focused on precision medicine for FGFR-driven diseases and is currently studying infigratinib and its potential to improve the irregular bone growth in achondroplasia by decreasing the overactivity of the FGFR3.  

The Goodwin team was led by Noelle Dubiansky, Emily Beman, Alex Hernandez, and Adam Bellack (IPTS); Michael Brodowski and Jessica Rothstein (IP); Alexandra Valenti (IP Litigation); Steven Tjoe (Regulatory & Compliance); Paul Jin (Antitrust); and Kristopher Ring and Kathleen Ryan (Private Equity); with invaluable assistance from Shaleena Alli-Rampersad.

For additional details, please read the press release and coverage in FiercePharma and Pharmaceutical Technology.